Replies to post #114613 on Amarantus Bioscience Holdings Inc (AMBS)

[joboggi]

I would wait to buy until a couple of months AFTER the RS. I do not know that company, but it is going straight up right now. And yes it was 18 months or so, maybe a little more, before it got some traction.

[a surfer]

Great example here! 20% gain the day of RS. 1 - 125 split.
Update on Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock

Download PDF
PRINCETON, N.J.-- Advaxis, Inc., (OTCQB: ADXS and ADXSD), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that the closing price of its stock was $5.87 on July 15, 2013, the first day of trading on a post reverse split basis, an increase of approximately 20% from the previous closing price of $4.875. This release updates the release “Advaxis Announces 1-for-125 Reverse Stock Split and Decrease in Authorized Shares of Common Stock” issued Monday, July 15. The original release follows:

Advaxis, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today a 1-for-125 reverse stock split of its common stock and a decrease in the number of its authorized shares of common stock from 1,000,000,000 to 25,000,000. The reverse stock split and the decrease in the number of authorized shares of common stock were authorized by Advaxis’ stockholders at the annual meeting of stockholders held on June 14, 2013.

Advaxis’ shares of common stock will trade on a post-split basis beginning on July 15, 2013. The ticker symbol will not change although a “D” will be appended to the trading symbol (ADXSD) for 20 trading days to alert the public regarding the reverse stock split. The new CUSIP number for Advaxis’ common stock post-reverse stock split will be 007624 208.

At the effective time of the reverse stock split, every 125 shares of Advaxis’ issued and outstanding common stock will automatically be combined into 1 issued and outstanding share of common stock without any change in the par value of the shares. This will reduce the number of outstanding common shares of Advaxis from approximately 609 million to approximately 4.9 million. Additional information can be found in a Form 8-K to be filed with the Securities and Exchange Commission.

“The reverse stock split does not fundamentally change stockholder value or the market capitalization of Advaxis, but we believe increasing the price per share will make our stock more attractive to a broader range of institutional and other investors and ultimately increase stockholder value,” commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis.

Proportionate voting rights and other rights of common stockholders will not be affected by the reverse stock split, other than as a result of the cashing out of fractional shares. Stockholders who would otherwise hold a fractional share of common stock will receive a cash payment in lieu of a fractional share. The outstanding preferred stock will not be affected by the reverse stock split.

It is not necessary for stockholders to exchange their existing stock certificates for new stock certificates in connection with the reverse stock split, although stockholders may do so if they wish. Please direct any questions you might have concerning the reverse stock split to your broker or our transfer agent, Securities Transfer Corporation, by calling 469-633-0101, ext. 112, or emailing [e-mail].